Aprea Therapeutics Reports Financial Developments and Clinical Progress for Quarter Ending June 30, 2026

Aprea Therapeutics, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded no grant revenue during the quarter, a decrease from $118,111 in the same period last year. Total operating expenses rose to $4.03 million, up from $3.51 million year-over-year, primarily driven by increased research and development costs associated with the ongoing Phase 1 study of its lead product candidate, APR-1051. The net loss for the quarter was $3.59 million, compared to a loss of $3.24 million in the prior year, reflecting a continued investment in clinical trials and operational activities.

In terms of financial position, Aprea's cash and cash equivalents increased significantly to $41.23 million as of June 30, 2026, compared to $14.60 million at the end of 2025. This increase was largely attributed to successful financing activities, including private placements that generated approximately $32.7 million in net proceeds during the first half of 2026. The company’s accumulated deficit now stands at $340.52 million, highlighting the ongoing costs associated with its clinical development programs.

Strategically, Aprea has focused on advancing its clinical pipeline, particularly with APR-1051, a WEE1 kinase inhibitor. The company has expanded its clinical trial sites from three to ten, aiming to accelerate patient enrollment, which is expected to reach 6 to 10 patients per month by the fourth quarter of 2026. Additionally, Aprea has closed the ABOYA-119 Phase I study for ATRN-119, its other product candidate, to concentrate resources on APR-1051. The company is also exploring potential combination therapies for ATRN-119 with leading academic centers.

Operationally, Aprea's research and development expenses for the first half of 2026 totaled $4.07 million, a slight decrease from $4.40 million in the same period last year. The company has reported a shift in focus towards its lead candidate, APR-1051, which has shown promising early clinical results, including confirmed partial responses in patients with specific cancer mutations. Aprea anticipates that its existing cash reserves will fund operations into the first quarter of 2028, although it acknowledges the need for additional financing to support ongoing and future development activities.

Looking ahead, Aprea Therapeutics remains committed to its clinical development strategy, with plans to report further clinical data from the APR-1051 study at a medical meeting in the fourth quarter of 2026. The company is also evaluating the potential for additional product candidates and collaborations to enhance its therapeutic offerings in the oncology space.